Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA.

Kazuyoshi FunatoNozomi MiyakeKazuma SekibaYu MiyakawaTakahiro SeimiyaChikako ShibataTakahiro KishikawaMotoyuki Otsuka

Published in: Hepatology communications (2023)

Cabozantinib has favorable therapeutic effects on HBV-related HCC because it inhibits HCC not only directly but also indirectly by means of inhibitory effects on HBV.

Keyphrases

hepatitis b virus
liver failure
transcription factor
metastatic renal cell carcinoma
cell proliferation
binding protein